Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients

PURPOSE: Umeclidinium/vilanterol (UMEC/VI) is a novel fixed dose combination of a long-acting muscarinic receptor antagonist (LAMA) and a long-acting beta 2 receptor antagonist (LABA) agent. This analysis evaluated the incremental cost-effectiveness ratio (ICER) of UMEC/VI compared with tiotropium (...

Descripción completa

Detalles Bibliográficos
Autores principales: Miravitlles, Marc, Gáldiz, Juan B, Huerta, Alicia, Villacampa, Alba, Carcedo, David, Garcia-Rio, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723026/
https://www.ncbi.nlm.nih.gov/pubmed/26848262
http://dx.doi.org/10.2147/COPD.S94006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723026/
https://www.ncbi.nlm.nih.gov/pubmed/26848262
http://dx.doi.org/10.2147/COPD.S94006

Ejemplares similares